Changing end points in breast-cancer drug approval--the Avastin story.
about
Lessons learned from the bevacizumab experienceThe G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.The evolution of Reference Drug Lists and Clinical Practice Guidelines in the public health system of a middle-income countryTargeted therapies for adrenocortical carcinoma: IGF and beyond.Clinical advances in the development of novel VEGFR2 inhibitors.How Do Payers Respond to Regulatory Actions? The Case of BevacizumabDesign and conduct of intervention-based research among cancer survivorsCan intensive longitudinal monitoring of individuals advance cancer research?Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.Targeting angiogenesis in metastatic breast cancerMedical Emergency Team: How do we play when we stay? Characterization of MET actions at the scene.Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapyWhen progressive disease does not mean treatment failure: reconsidering the criteria for progression.Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.Co-option of pre-existing vascular beds in adipose tissue controls tumor growth rates and angiogenesis.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques.Role of randomized phase III trials in an era of effective targeted therapies.Bevacizumab: overview of the literature.Sorafenib in locally advanced or metastatic breast cancer.Neoadjuvant treatments for triple-negative breast cancer (TNBC).Therapeutic application of monoclonal antibodies in cancer: advances and challenges.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Bevacizumab induces A549 cell apoptosis through the mechanism of endoplasmic reticulum stress in vitro.Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
Q26852509-614DAFBC-EACE-4E1D-AC13-FE5C8621010EQ33623170-E0071E52-C1C7-409F-B83E-699226B7CD47Q34065328-2EBA4E3C-EE6E-4980-A593-4F9108D5960CQ34101433-93BA66CE-3AFF-46E5-9A8B-F92A0DC8908DQ34658366-790CAAA2-C12D-4520-91E5-03B9F8604B2CQ35866147-154070D6-2169-4AE1-946E-DCAEBC84D11FQ35955339-C8872702-ADEE-4A0C-B051-E89640851571Q35989936-C2C21EB9-C88F-41B5-8E36-8A518C717B2CQ36102859-3E642847-596E-466D-B616-B597148B6F29Q36115981-1E7DEDA1-5236-4797-98AB-ADA049FE7D69Q36174876-05687B67-B965-4927-B2CC-04AEEB979535Q36182795-005570B3-7129-4671-AE25-A223DC004ACBQ36714331-BBC8E6CD-2C58-479E-BC48-663B3DEC54A1Q36821570-1172357B-3835-4232-9E88-A83374C0C91CQ37003248-39F0FAC9-973D-4793-AA32-C2A78E23F497Q37234829-7E413A2A-2B10-47EE-899B-4762336D2CEDQ37260920-10C2AB47-E28C-4D04-B2CE-6B726F9B8567Q37437470-B747FF59-2CB7-4F56-BA18-6D72CA6DF6B6Q37533025-E638A1BC-1652-416A-8A13-6CF0D5C445AAQ37935712-0AC33401-4F61-403D-B7FA-FD6D15F8649FQ37964935-5DA34161-D2B6-4D5B-9175-4CFA8FBCC821Q38010797-6F61D9F1-9F85-46EF-B197-B1335CBE084DQ38012156-11F75035-E0D6-4807-87F2-0F019B140316Q38046580-8BCA8C64-2B28-470E-BE97-04D0D768DC82Q38057179-281CA6F8-61C1-4B1F-B43E-756C0D189457Q38232368-3339B8C1-A139-447A-BA94-7939DB298EA0Q38851240-F97BAF6A-0655-465B-A3A2-AC7E3D1647E0Q43077324-F832B038-07D1-4ABC-84A3-31F34A822A0AQ58780996-288F9FF0-E1B1-46E0-AE1A-C238FA9453FE
P2860
Changing end points in breast-cancer drug approval--the Avastin story.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Changing end points in breast-cancer drug approval--the Avastin story.
@en
Changing end points in breast-cancer drug approval--the Avastin story.
@nl
type
label
Changing end points in breast-cancer drug approval--the Avastin story.
@en
Changing end points in breast-cancer drug approval--the Avastin story.
@nl
prefLabel
Changing end points in breast-cancer drug approval--the Avastin story.
@en
Changing end points in breast-cancer drug approval--the Avastin story.
@nl
P356
P1476
Changing end points in breast-cancer drug approval--the Avastin story.
@en
P2093
Ralph B D'Agostino
P356
10.1056/NEJMP1106984
P407
P577
2011-06-27T00:00:00Z